APGE insider buying and SEC filings, explained
Apogee Therapeutics, Inc. · CIK 1974640
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Industry (SIC)
- Biological Products, (No Diagnostic Substances)
- Fiscal year end
- Dec 31
- Former names
- Apogee Therapeutics, LLC
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$133.5M
Planned sales (10b5-1)
$40.4M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Aug 5, 2026 | Planned (10b5-1) | Carl Dambkowski (Chief Medical Officer) sold 5,500 shares at $134.17 ($738K), marked as a 10b5-1 plan trade. Holdings down 3% to 168,498 shares. | SEC filing Filed Aug 7, 2026 |
| Jul 8, 2026 | Planned (10b5-1) | Michael Thomas Henderson (CEO and Director) sold 20,000 shares at about $133.63 ($2.7M), marked as a 10b5-1 plan trade. Holdings down 2% to 995,987 shares. | SEC filing Filed Jul 10, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Carl Dambkowski (Chief Medical Officer) sold 5,500 shares at $132.74 ($730K), marked as a 10b5-1 plan trade. Holdings down 3% to 177,873 shares. | SEC filing Filed Jul 2, 2026 |
| Jun 22, 2026 | Planned (10b5-1) | Carl Dambkowski (Chief Medical Officer) sold 26,400 shares at about $132.60 ($3.5M), marked as a 10b5-1 plan trade. Holdings down 13% to 179,248 shares. | SEC filing Filed Jun 24, 2026 |
| Jun 22, 2026 | Planned (10b5-1) | Michael Thomas Henderson (CEO and Director) sold 80,000 shares at about $132.54 ($10.6M), marked as a 10b5-1 plan trade. Holdings down 7% to 1,015,987 shares. | SEC filing Filed Jun 24, 2026 |
| Jun 10, 2026 | Planned (10b5-1) | Michael Thomas Henderson (CEO and Director) sold 20,000 shares at about $83.38 ($1.7M), marked as a 10b5-1 plan trade. Holdings down 2% to 1,095,987 shares. | SEC filing Filed Jun 12, 2026 |
| Jun 3, 2026 | Planned (10b5-1) | Carl Dambkowski (Chief Medical Officer) sold 5,500 shares at $78.71 ($433K), marked as a 10b5-1 plan trade. Holdings down 3% to 205,648 shares. | SEC filing Filed Jun 5, 2026 |
| May 13, 2026 | Planned (10b5-1) | Michael Thomas Henderson (CEO and Director) sold 20,000 shares at about $82.09 ($1.6M), marked as a 10b5-1 plan trade. Holdings down 2% to 1,115,987 shares. | SEC filing Filed May 15, 2026 |
| May 6, 2026 | Planned (10b5-1) | Carl Dambkowski (Chief Medical Officer) sold 5,500 shares at about $84.14 ($463K), marked as a 10b5-1 plan trade. Holdings down 3% to 207,023 shares. | SEC filing Filed May 8, 2026 |
| May 1, 2026 | Planned (10b5-1) | Jane Henderson (CFO) sold 2,000 shares at about $82.04 ($164K), marked as a 10b5-1 plan trade. Holdings down 1% to 173,371 shares. | SEC filing Filed May 4, 2026 |
| Apr 16, 2026 | Planned (10b5-1) | Jane Henderson (CFO) sold 2,000 shares at $90.00 ($180K), marked as a 10b5-1 plan trade. Holdings down 1% to 175,371 shares. | SEC filing Filed Apr 17, 2026 |
| Apr 8, 2026 | Planned (10b5-1) | Michael Thomas Henderson (CEO and Director) sold 20,000 shares at about $82.58 ($1.7M), marked as a 10b5-1 plan trade. Holdings down 2% to 1,132,987 shares. | SEC filing Filed Apr 10, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Carl Dambkowski (Chief Medical Officer) sold 5,500 shares at about $84.84 ($467K), marked as a 10b5-1 plan trade. Holdings down 3% to 208,398 shares. | SEC filing Filed Apr 3, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Jane Henderson (CFO) sold 2,000 shares at about $85.01 ($170K), marked as a 10b5-1 plan trade. Holdings down 1% to 177,371 shares. | SEC filing Filed Apr 3, 2026 |
| Mar 25, 2026 | Planned (10b5-1) | Jane Henderson (CFO) sold 2,000 shares at $85.00 ($170K), marked as a 10b5-1 plan trade. Holdings down 1% to 179,371 shares. | SEC filing Filed Mar 27, 2026 |
| Mar 11, 2026 | Planned (10b5-1) | Michael Thomas Henderson (CEO and Director) sold 20,000 shares at about $74.78 ($1.5M), marked as a 10b5-1 plan trade. Holdings down 2% to 1,152,987 shares. | SEC filing Filed Mar 13, 2026 |
| Mar 4, 2026 | Planned (10b5-1) | Carl Dambkowski (Chief Medical Officer) sold 5,500 shares at about $71.06 ($391K), marked as a 10b5-1 plan trade. Holdings down 3% to 209,773 shares. | SEC filing Filed Mar 6, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Jane Henderson (CFO) sold 2,000 shares at about $70.22 ($140K), marked as a 10b5-1 plan trade. Holdings down 1% to 181,371 shares. | SEC filing Filed Mar 4, 2026 |
| Feb 11, 2026 | Planned (10b5-1) | Michael Thomas Henderson (CEO and Director) sold 20,000 shares at about $63.35 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 2% to 1,172,987 shares. | SEC filing Filed Feb 13, 2026 |
| Feb 4, 2026 | Planned (10b5-1) | Carl Dambkowski (Chief Medical Officer) sold 5,500 shares at about $65.79 ($362K), marked as a 10b5-1 plan trade. Holdings down 3% to 211,148 shares. | SEC filing Filed Feb 4, 2026 |
| Feb 2, 2026 | Planned (10b5-1) | Jane Henderson (CFO) sold 2,000 shares at about $65.81 ($132K), marked as a 10b5-1 plan trade. Holdings down 1% to 183,371 shares. | SEC filing Filed Feb 4, 2026 |
| Jan 22, 2026 | Sale | Peter Evan Harwin (Director) sold 1,750,000 shares indirectly (by entity) at $76.30 ($133.5M). Holdings by entity down 85% to 298,647 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 3 other reporting owners. | SEC filing Filed Jan 22, 2026 |
| Jan 14, 2026 | Planned (10b5-1) | Michael Thomas Henderson (CEO and Director) sold 20,000 shares at about $81.11 ($1.6M), marked as a 10b5-1 plan trade. Holdings down 2% to 1,192,987 shares. | SEC filing Filed Jan 16, 2026 |
| Jan 7, 2026 | Planned (10b5-1) | Carl Dambkowski (Chief Medical Officer) sold 18,700 shares at about $77.84 ($1.5M), marked as a 10b5-1 plan trade. Holdings down 8% to 212,523 shares. | SEC filing Filed Jan 9, 2026 |
| Jan 2–6, 2026 | Planned (10b5-1) | Jane Henderson (CFO) sold 8,000 shares between Jan 2 and Jan 6 at about $76.14 ($609K), marked as a 10b5-1 plan trade. Holdings down 4% to 185,371 shares. | SEC filing Filed Jan 6, 2026 |
| Dec 19, 2025 | Planned (10b5-1) | Jane Henderson (CFO) sold 1,500 shares at $80.00 ($120K), marked as a 10b5-1 plan trade. Holdings down 1% to 193,371 shares. | SEC filing Filed Dec 23, 2025 |
| Dec 10, 2025 | Planned (10b5-1) | Michael Thomas Henderson (CEO and Director) sold 20,000 shares at about $75.38 ($1.5M), marked as a 10b5-1 plan trade. Holdings down 2% to 1,212,987 shares. | SEC filing Filed Dec 12, 2025 |
| Dec 4, 2025 | Planned (10b5-1) | Carl Dambkowski (Chief Medical Officer) sold 10,900 shares at about $75.00 ($818K), marked as a 10b5-1 plan trade. Holdings down 4% to 271,108 shares. | SEC filing Filed Dec 5, 2025 |
| Dec 4, 2025 | Planned (10b5-1) | Jane Henderson (CFO) sold 1,500 shares at $75.00 ($113K), marked as a 10b5-1 plan trade. Holdings down 1% to 194,871 shares. | SEC filing Filed Dec 5, 2025 |
| Dec 4, 2025 | Planned (10b5-1) | Michael Thomas Henderson (CEO and Director) sold 40,000 shares at about $75.01 ($3.0M), marked as a 10b5-1 plan trade. Holdings down 3% to 1,232,987 shares. | SEC filing Filed Dec 5, 2025 |
| Nov 25, 2025 | Planned (10b5-1) | Jane Henderson (CFO) sold 1,500 shares at $70.00 ($105K), marked as a 10b5-1 plan trade. Holdings down 1% to 196,371 shares. | SEC filing Filed Nov 28, 2025 |
| Nov 14, 2025 | Planned (10b5-1) | Jane Henderson (CFO) sold 2,000 shares at $65.00 ($130K), marked as a 10b5-1 plan trade. Holdings down 1% to 197,871 shares. | SEC filing Filed Nov 14, 2025 |
| Nov 13, 2025 | Planned (10b5-1) | Michael Thomas Henderson (CEO and Director) sold 20,000 shares at about $63.01 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 2% to 1,272,987 shares. | SEC filing Filed Nov 13, 2025 |
| Nov 11, 2025 | Planned (10b5-1) | Jane Henderson (CFO) sold 1,000 shares at $60.00 ($60K), marked as a 10b5-1 plan trade. Holdings down <1% to 199,871 shares. | SEC filing Filed Nov 13, 2025 |
| Nov 5, 2025 | Planned (10b5-1) | Carl Dambkowski (Chief Medical Officer) sold 10,785 shares at about $55.07 ($594K), marked as a 10b5-1 plan trade. Holdings down 4% to 282,008 shares. | SEC filing Filed Nov 7, 2025 |
32 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow APGE in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.